Findings from a meta-analysis of over 125 clinical trials led the agency to require a class-wide label change.
News|Articles|February 3, 2003
New Product Newswire
New Product Newswire
Advertisement
Advertisement
Related to this article
Gilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.
Advertisement
Advertisement
Trending on Drug Topics
1
High Triglycerides Independently Linked with Severe COVID-19 Death
2
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
3
US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains
4
ACCESS to Pharmacy Care Model Lets Pharmacists Bill for Chronic Care
5